Low response rates in open-label, nonrandomized study raise questions about efficacy of the first-in-class EZH2 inhibitor relative to drugs currently used to treat the rare cancer, FDA says in advisory committee briefing document; retrospective natural history study also cannot be used to determine whether patients have better outcomes with tazemetostat than with available therapies.
The limited clinical experience and lack of reliable comparative data for Epizyme Inc.’s tazemetostat raise concerns about the drug’s efficacy in patients with epithelioid sarcoma, the US Food and Drug Administration says.
In a briefing document released ahead of the Oncologic Drugs Advisory Committee meeting on 18 December, the agency said...